MedTrace Logo

Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea

NCT03053700 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-10-31

No results posted yet for this study

Summary

This is an interventional and prospective study. The study is designed to evaluate the additional benefits of a combination of IPL treatment and local application of Bromonide 0.33% gel in the treatment of erythematotelangiectatic (ETR) and papulopustular (PPR).

Conditions

  • Rosacea

Interventions

DRUG

Bromonide 0.33% gel

Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.

DEVICE

Intense Pulsed Light (M22)

Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Assi Levi, Dr. · Rabin Medical center, Petach Tikva

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2019-01-02
Completion
2019-01-02

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03053700 on ClinicalTrials.gov